Impax Laboratories News

There's a big difference between promise and practicality. Medco Health Solutions is partnering with federal drug regulators to move beyond the potential of personalized medicine and determine how it can be ...

Astrazeneca sued Apotex and Impax for infringing patents of "pharmaceutical preparations containing omeprazole, the active ingredient in Prilosec." Filing ANDAs prompted the patent assertion.

A unit of Johnson & Johnson, the world's largest maker of health-care products, sued generic drugmaker Hayward-based Impax Laboratories Inc., alleging infringement of a patent for the painkiller Ultram ER.

The following is excerpted from a July 22, 2008 IMPAX press release at Business Wire : IMPAX Laboratories, Inc.

The following is excerpted from a July 22, 2008 IMPAX press release at Business Wire : IMPAX Laboratories, Inc.

Generic drug maker Impax Laboratories Inc. has been sued over its copy of a drug to treat prostate enlargement.

Wyeth and Impax Laboratories Inc. said late Wednesday the companies' settlement of their patent infringement lawsuit related to Impax's generic version of Wyeth's Effexor XR has received court approval.

Please be advised the following issue has been repurchased for EUR 100,000 on 20 Jun 08 - 06/27/2008 - 09:17 AM GRASBRUNN & MUNICH, Germany-- --Wirecard AG has taken extensive measures against the short selling ...

Generic drug maker Impax Laboratories Inc. had its stock registration revoked by the Securities and Exchange Commission.

Impax Laboratories of Hayward that the SEC issued an order revoking the registration of the Company's common stock.

IMPAX Laboratories, Inc. today announced that Arthur A. Koch, Jr., its senior vice president and chief financial officer, will present at the Citi Investment Research 2008 Global Healthcare Conference on ... via Earth Times

“This suit is just a delaying tactic to prevent patients from accessing generic drugs sooner”

Impax Laboratories Inc. said Thursday that it has been sued for patent infringement by Pfizer Inc. via East Bay Business Times

Advanced Cell Technology, Inc. today announced that it completed discussions with the Food and Drug Administration regarding its retinal - 02/01/2008 - 09:27 AM LOWELL, Ark.-- --J.B. Hunt Transport Services, ... via Business Wire

Die M's Science Corporation , ein auf die Entdeckung und Entwicklung von Arzneimitteln in der klinischen Erprobungsphase - HAYWARD, Calif.-- --IMPAX Laboratories, Inc. via Business Wire

“We will continue to pursue discussions with the FDA concerning this decision and we are evaluating all options for the product.”

Jan 30, 2008 - IMPAX Laboratories, Inc. today announced that it has received a non-approvable letter from the U.S. Food and Drug Administration concerning its new drug application and subsequent submissions for ... via Med Ad News

“Lidoderm remains a solid asset, but without strong additions to its portfolio, we find that Endo will have a hard time standing alone.”

Investors lifted shares of pain drug developer Endo Pharmaceuticals Holdings Inc. via Forbes

“Medicis faces important challenges in 2008, as the consumer slowdown could affect the aesthetics business and spending will increase to prepare for the Reloxin launch at year-end.”

Shares of Scottsdale-based Medicis Pharmaceutical Corp., which makes skin medications, fell sharply to a new annual low after Impax Laboratories challenged a patent for its Solodyn drug for the treatment of ... via East Valley Tribune

IMPAX Laboratories, Inc. today announced that Arthur A. Koch, Jr., its senior vice president and chief financial officer, will present at JP Morgan ' s 26th Annual Healthcare Conference on Wednesday, January 9 ... via Business Wire